

Cite this: *Chem. Sci.*, 2019, 10, 1457 All publication charges for this article have been paid for by the Royal Society of Chemistry

# Heterologous biosynthesis of elsinochrome A sheds light on the formation of the photosensitive perylenequinone system†

Jinyu Hu, <sup>a</sup> Farzaneh Sarrami,<sup>a</sup> Hang Li, <sup>a</sup> Guozhi Zhang,<sup>a</sup> Keith A. Stubbs, <sup>a</sup> Ernest Lacey, <sup>bc</sup> Scott G. Stewart, <sup>a</sup> Amir Karton, <sup>a</sup> Andrew M. Piggott <sup>c</sup> and Yit-Heng Chooi <sup>\*a</sup>

Perylenequinones are a class of aromatic polyketides characterised by a highly conjugated pentacyclic core, which confers them with potent light-induced bioactivities and unique photophysical properties. Despite the biosynthetic gene clusters for the perylenequinones elsinochrome A (**1**), cercosporin (**4**) and hypocrellin A (**6**) being recently identified, key biosynthetic aspects remain elusive. Here, we first expressed the intact *elc* gene cluster encoding **1** from the wheat pathogen *Parastagonospora nodorum* heterologously in *Aspergillus nidulans* on a yeast-fungal artificial chromosome (YFAC). This led to the identification of a novel flavin-dependent monooxygenase, ElcH, responsible for oxidative enolate coupling of a perylenequinone intermediate to the hexacyclic dihydrobenzo(*ghi*)perylenequinone in **1**. In the absence of ElcH, the perylenequinone intermediate formed a hexacyclic cyclohepta(*ghi*)perylenequinone system *via* an intramolecular aldol reaction resulting in **6** and a novel hypocrellin **12** with opposite helicity to **1**. Theoretical calculations supported that **6** and **12** resulted from atropisomerisation upon formation of the 7-membered ring. Using a bottom-up pathway reconstruction approach on a tripartite YFAC system developed in this study, we uncovered that both a berberine bridge enzyme-like oxidase ElcE and a laccase-like multicopper oxidase ElcG are involved in the double coupling of two naphthol intermediates to form the perylenequinone core. Gene swapping with the homologs from the biosynthetic pathway of **4** showed that cognate pairing of the two classes of oxidases is required for the formation of the perylenequinone core, suggesting the involvement of protein–protein interactions.

Received 29th June 2018  
Accepted 21st November 2018

DOI: 10.1039/c8sc02870b

rsc.li/chemical-science

## Introduction

Perylenequinones are a class of polyketide-derived photosensitisers and dark-coloured pigments that share a pentacyclic 4,9-dihydroxy-3,10-perylenequinone core (Fig. 1). The fungal perylenequinones, known as the Class B perylenequinones, are characterised by the stereogenic C7,C7' side chains as well as the oxidative substitutions at C2,C2' and C6,C6'.<sup>1</sup> The substitutions on the perylenequinone core render the structures non-planar, resulting in axial chirality classified as either (*M*) or (*P*) (Fig. 1). These compounds can absorb light to generate reactive oxygen species (ROS) and possess a wide range of bioactivities, most notably their protein kinase C inhibitory activity, and they

have potential application in photodynamic cancer therapy.<sup>1–3</sup> Well-known members of this class of compounds include elsinochromes **1–3**, cercosporin **4**, hypocrellins (*e.g.* **5–6**) and calphostins (Fig. 1). Due to their photochemical properties, cytotoxic activities, interesting axial chirality, and their involvement in fungal virulence, perylenequinones have attracted much interest from both chemists and biologists.<sup>3,4</sup>

To date, the biosynthetic gene clusters (BGCs) responsible for the biosynthesis of the three Class B perylenequinones, **4**, **6** and **3**, have been identified (Fig. 2A). Cercosporin **4** was the first perylenequinone to be isolated.<sup>5</sup> It has a typical pentacyclic perylenequinone core, but is distinguished from other members of the class by the presence of an asymmetric 1,3-dioxepine moiety. The *CTB* cluster for biosynthesis of **4** from *Cercospora nicotianae* was also the first to be identified and several studies of the genes have been reported (Fig. 2B).<sup>6,7</sup> Hypocrellins **5–6** and related analogues are known to be present in traditional Chinese medicine preparations derived from *Hypocrella bambusae* and *Shiraia bambusicola* parasitising on bamboo, which have been used to treat vitiligo, psoriasis, rheumatoid arthritis and other diseases.<sup>8</sup> The hypocrellins are

<sup>a</sup>School of Molecular Sciences, University of Western Australia, Perth, WA 6009, Australia. E-mail: yitheng.chooi@uwa.edu.au<sup>b</sup>Microbial Screening Technologies, Smithfield, NSW 2164, Australia<sup>c</sup>Department of Molecular Sciences, Macquarie University, Sydney, NSW 2109, Australia

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc02870b






Fig. 1 Class B perylenequinones grouped into three subclasses based on the core structures (box).

characterised by the hexacyclic cyclohepta(*ghi*)perylenequinone core (Fig. 1). The *HYP* cluster for **6** was identified in *Shiraia* sp. Slf14 based on gene expression correlation,<sup>9</sup> and subsequently verified by targeted gene deletion.<sup>10</sup> Elsinochromes **1–3** are characterised by the hexacyclic dihydrobenzo(*ghi*)perylenequinone core (Fig. 1). Our group recently identified the *elc* cluster from the wheat pathogen *Parastagonospora nodorum* for **3**, which has been shown to be important for its virulence.<sup>11</sup>

The biosynthesis of perylenequinone has been shown to start from a common aromatic polyketide precursor, nor-toralactone (**7**), which is synthesised by the non-reducing polyketide synthase (PKS) CTB1/ElcA (Fig. 2B).<sup>11,12</sup> More insights into the

biosynthesis of perylenequinones have been gained recently with the characterisation of a bifunctional enzyme CTB3, which possesses fused *O*-methyltransferase and flavin-dependent monooxygenase domains, from the *C. nicotianae* CTB cluster. This enzyme is responsible for hydroxylation, ring opening, decarboxylation and *O*-methylation of the nor-toralactone polyketide precursor synthesised by CTB1 PKS (Fig. 2B).<sup>7</sup> Nevertheless, the key steps in perylenequinone biosynthesis, *i.e.* the oxidative coupling steps to generate the pentacyclic core, the enolate coupling to yield the hexacyclic system in **1–3**, and the 7-membered ring in **5–6**, remained unresolved.

The *elc*, *CTB* and *HYP* gene clusters contain multiple shared homologs (Fig. 2A and Table S4†).<sup>11,13</sup> The most recent study reported that the *CTB* cluster,<sup>13</sup> like the *elc* and *HYP* clusters, encodes homologs of ElcF (fasciclin domain-containing protein) and ElcG (laccase-like multicopper oxidase (LMCO)), which were found in the *HYP* cluster but were missing in the originally defined *CTB* cluster (Fig. 2A).<sup>6</sup> We hypothesised that the shared homologs in the three clusters encode common biosynthetic steps and are responsible for the pentacyclic perylenequinone core and the common substitutions (Fig. 2B). Herein, we shed light on the biosynthesis of Class B perylenequinones by reconstituting the pathway of **1** in *Aspergillus nidulans*. We demonstrate that formation of the three C–C bridges between the two naphthol monomers for **1** involves three distinct classes of oxidative enzymes.

## Results

### Heterologous expression of putative *elc* cluster produced two hypocrellins

To determine whether the putative *elc* cluster has all the genes required to synthesise **1–3**, we first cloned the entire 27 kbp *elc* cluster onto a yeast-fungal hybrid artificial chromosome (YFAC) system, pYFAC-CH1, containing *CEN/ARS* and *AMA1* for DNA




Fig. 2 The biosynthetic gene clusters for **4** (*CTB*), **1** (*elc*) and **6** (*HYP*) (A) and their proposed biosynthetic pathway (B).



replication in *Saccharomyces cerevisiae* and *A. nidulans* derived from pKW20088 vector backbone.<sup>14</sup> The 27-kbp fragment containing the entire putative *elc* cluster (*elcA-G* and *elcR*) was cloned into pYFAC-CH1, resulting in pYFAC-CH6 (Table S3†). An engineered *A. nidulans* strain LO7890 with low metabolic background was used as the heterologous host.<sup>15</sup> Expression of the *elc* cluster was achieved by replacing the native promoter of the pathway-specific transcription factor gene, *elcR*,<sup>11</sup> with a  $P_{alcA}$  alcohol-inducible promoter. LC-DAD-MS analysis of the acetone mycelium extract from a four-day post-induction culture showed that *A. nidulans* harbouring pYFAC-CH6 produced two new compounds, both of which had a mass ion of  $m/z$  547 [ $M + H$ ]<sup>+</sup> (2 Da less in mass compared to 3) and near-identical UV-vis spectra to elsinochromes 1–3 (Fig. 3A). LC-DAD-MS comparison with standards of 1–3 showed that their retention times ( $t_R$ ) were different from 2 but close to 1 (Fig. S2†). The two compounds were isolated from scaled-up *A. nidulans* liquid culture (see ESI†). Extensive 1D and 2D NMR analysis of the compound 12 eluting earlier at 7.8 min (Fig. 3A) confirmed its structure to have the same atom connectivity as 5/6 with a cyclohepta(*ghi*)perylenequinone core (Table S5, Fig. S14–S18†). This prompted us to compare the two compounds with a standard of hypocrellin A 6. LC-DAD-MS analysis showed that the compound eluting later at 7.95 min had the same  $t_R$  as 6

(Fig. 3A). The <sup>1</sup>H NMR data along with the ECD spectrum supported that the compound is identical to 6, which has the (*P*) helicity (Table S7, Fig. S3, S20 and S21†).

Compound 12 eluted slightly earlier than 6 on LC-DAD-MS (Fig. 3A). The minor <sup>1</sup>H NMR chemical shift differences for the signals around the C16–C17 stereogenic centres suggested that 12 is a diastereomer of 6. We performed further 1D NOESY experiments on 12 to deduce its relative configuration (Table S6, Fig. S4 and S19†). Key NOESY correlations narrowed down the structure of 12 to a pair of enantiomers – either 16*R* and 17*S* for the (*P*) helicity or 16*S* and 17*R* for the (*M*) helicity (Fig. S4†). ECD spectroscopic analysis showed that 12 shared almost identical Cotton effects with 6 between 240 nm and 600 nm, except at around 295 nm, which had an opposite Cotton effect to that of 6 (Fig. S3†). Cotton effects at the 250–600 nm region have been associated with the helicity of perylenequinones.<sup>16</sup> This suggested that 12, like 6, adopts the (*P*) helicity, but with the opposite configuration (16*R* and 17*S*) on the 7-membered ring compared to 6, and is thus an atropisomer of 5 (Fig. 3A). The elucidation of 12 and 6 as members of hypocrellins verified that the putative *elc* cluster contains all the genes required for the construction of the perylenequinone core but not 1–3, suggesting that there may be still genes missing in the *elc* cluster on the pYFAC-CH6.

### A previously unidentified flavin-dependent monooxygenase gene *elcH* encodes elsinochrome synthase

Reviewing previous *in planta* transcriptomic data of *P. nodorum*<sup>17,18</sup> revealed that another gene, *SNOG\_08601* encoding a putative flavin-dependent monooxygenase (FMO), located approximately 8 kbp upstream of the *elc* cluster was co-upregulated with other genes in the cluster (Fig. S5†). Interestingly, a homolog of *SNOG\_08601*, *HYP7*, can be found in the *HYP* cluster (Fig. 2A and Table S4†). To determine the role of *SNOG\_08601* (herein named *elcH*) in the biosynthesis of 1–3, pYFAC-CH23 carrying only *elcH* under  $P_{alcA}$  regulation was constructed and co-expressed with pYFAC-CH6 (containing *P. nodorum elc* cluster with  $P_{alcA}:elcR$ ). LC-DAD-MS analysis of the four-day culture extract detected a new peak with  $m/z$  545 [ $M + H$ ]<sup>+</sup> and a small amount of 12 and 6 (Fig. 3). The new compound matched the  $t_R$  and ion mass of the standard for 1. <sup>1</sup>H, <sup>13</sup>C, and 2D NMR analysis of the new compound confirmed its structure to be 1 (Table S8, Fig. S22–S25†). As expected, the ECD spectrum of 1 was identical to that of the 1 standard and nearly identical to that of 3 isolated from *P. nodorum* (Fig. S3†), thus confirming its (*M*) helicity. In a parallel experiment, the *elcH* gene with its native *P. nodorum* promoter region was inserted into pYFAC-CH6, resulting in pYFAC-CH26. Compound 1 could be detected as the major product in the post-induction culture of *A. nidulans* pYFAC-CH27, along with trace amounts of 12 and 6. This result indicates that *elcH* is indeed co-regulated with other *elc* genes by the pathway-specific transcriptional regulator ElcR.

### Heterologous expression of *elcA/B/D/E/F/G* reconstituted the biosynthesis of 12 and 6 and yielded novel naphthol derivatives

To elucidate the biosynthesis, we initially developed an *in vivo* YFAC editing technique in yeast based on the available yeast




Fig. 3 Heterologous biosynthesis of 12, 6 (A) and 1 (B). LC-DAD chromatograms and extracted ion chromatograms (EIC) of *A. nidulans* cultures harbouring the different YFAC constructs. Blue and red rounded rectangles represent YFAC vector backbones pYFAC-CH1 and -CH2, respectively. (Box) UV-vis spectra comparison of 12, 6 and 1.



CRISPR-Cas9 system (Fig. S6†).<sup>19</sup> Homology modelling by Phyre2<sup>20</sup> showed that ElcE is a flavo-oxidase belonging to the berberine bridge enzyme-like oxidase (BBEO) family (Fig. S7†), which are known to catalyse C–C bond formation.<sup>21</sup> On the other hand, *elcG* encodes a LMCO known to catalyse radical coupling reactions.<sup>21</sup> Thus, we proposed *elcE* and *elcG* to be involved in the dimerisation of the naphthol **10** and targeted the two genes. We successfully disrupted *elcE* by CRISPR-Cas9 editing on the pYFAC-CH6 (pYFAC-CH9) and constructed a truncated version of pYFAC-CH6 without *elcG* (pYFAC-CH7) (Table S3†). LC-DAD-MS analysis of *A. nidulans* culture extracts for both mutant constructs showed that the production of **12** and **6** was completely abolished (Fig. S8†), suggesting that *elcE* and *elcG* are important for the biosynthesis of perylenequinones. However, there was no pathway intermediate accumulated. Similar results were observed when *elcG* was deleted in the *P. nodorum* *elcR*-OE strain producing **3** in the previous work (data not shown)<sup>11</sup> and in the most recent study where the *elcG* homolog in the **4** pathway, *CTB12*, was deleted in *C. beticola*.<sup>13</sup>

Since no further biosynthetic insight could be gained from the gene disruption approach, we took an alternative bottom-up approach reconstructing the *elc* cluster by cloning each gene in the *elc* cluster under the regulation of *A. nidulans* alcohol-inducible promoters<sup>22</sup> on a tripartite YFAC system. pYFAC-CH2 with a *pyrG* marker was constructed to contain a  $P_{alcA}$  promoter, a bidirectional  $P_{alcS/M}$  promoter and a  $P_{aldA}$  along with terminators in between (Fig. S1†). The system was expanded to two other auxotrophic markers, *riboB* (pYFAC-CH3) and *pyroA* (pYFAC-CH4), respectively. Together, the tripartite YFAC system is capable of inducible expression of up to 12 genes and has been used recently for genome mining of novel phytotoxic  $\alpha$ -pyrones from *P. nodorum*.<sup>23</sup>

An *elcA* expression plasmid pYFAC-CH10, which produced **7** in *A. nidulans*, was already constructed in previous work.<sup>11</sup> Here, a new peak with  $m/z$  273  $[M + H]^+$  was detected in the *A. nidulans* pYFAC-CH10/14 culture co-expressing *elcA* and *elcB*-MT (truncated *elcB* encoding only the *O*-methyltransferase domain), which was isolated and confirmed by NMR to be toralactone **8** (Fig. 4A-i and S26†). This is in agreement with the previous *in vitro* work on CTB3-MT (*ElcB* homolog).<sup>7</sup> Co-expression of intact *elcB* with *elcA* resulted in complete conversion of **8** to three new compounds, **13**–**15**, in the culture (Fig. 4A-ii). Compound **15** was found to have an  $m/z$  of 277  $[M + H]^+$ , which has an identical mass to cercoquinone A and D observed previously.<sup>7</sup> However, due to poor stability and yield, we were unable to obtain sufficient quantities of **15** for NMR analysis.

Compounds **13** and **14** possessed identical UV-vis spectra and their mass ions corresponded to  $m/z$  of 360  $[M + H]^+$  and 417  $[M + H]^+$ , respectively. The two compounds were isolated as water-soluble purple pigments. The observed high-resolution mass ions for **13** were 360.0525  $[M + H]^+/314.0501 [M - H - CO_2]^-$ , which corresponds to the molecular formula  $C_{17}H_{13}O_6NS$  (calculated  $m/z$  360.0536  $[M + H]^+/314.0501 [M - H - CO_2]^-$ ) (Fig. S9†). The high resolution mass for **14** was measured as  $m/z$  417.0742  $[M + H]^+/415.0623 [M - H]^-$ , which is consistent with  $C_{19}H_{16}O_7N_2S$  (calculated  $m/z$  417.0751  $[M + H]^+/$




Fig. 4 Bottom-up heterologous reconstruction of pathway to the hypocrellins **12** and **6**. (A) LC-DAD chromatograms of *A. nidulans* strain harbouring the various constructs (i–vi) (also see Fig. S10†). Blue, red and green rounded rectangles represent the different YFAC vector backbone pYFAC-CH1–3, respectively. (B) Compounds isolated from these *A. nidulans* cultures.

415.0605  $[M - H]^-$ ) (Fig. S9†). Based on extensive analysis of 1D and 2D NMR data for **13** in  $D_2O$  (Table S9, Fig. S27–S31†) and **14** (Table S11, Fig. S32–S37†) in  $DMSO-d_6$ , we identified the presence of a cysteine moiety bridging C1 and C8 of the naphthol unit in both **13** and **14**, with **14** containing an additional glycine residue connected to the cysteine *via* an amide bond (Fig. 4B). The proposed structures of **13** and **14** were supported by density functional theory (DFT) calculations (B3LYP/def-TZVP) of the  $^{13}C$  NMR shielding tensors for **13**, which showed an excellent correlation with all experimental  $^{13}C$  chemical shifts (Table S10†). We reasoned that **13** and **14** were derived from the proposed naphthol intermediate **9** as a result of the glutathione *S*-transferase (GST) detoxification pathway endogenous to the *A. nidulans* host.

Next, pYFAC-CH16 carrying *elcD* was co-expressed with pYFAC-CH10 and pYFAC-CH13. Interestingly, this combination of genes (*elcA/B/D*) resulted in the accumulation of one major new compound **16**, which has an  $m/z$  of 789  $[M + H]^+$ , almost



three times the mass of the expected dimethoxy-naphthol **10** (Fig. 4a-iii). The high-resolution mass ions of **16** were consistent with the molecular formula  $C_{43}H_{32}O_{15}$  (observed  $m/z$  789.1788  $[M + H]^+$ /787.1685  $[M - H]^-$ , calculated 789.1814  $[M + H]^+$ /787.1668  $[M - H]^-$ ) (Fig. S9<sup>†</sup>). The NMR data for **16** in DMSO- $d_6$  and D<sub>2</sub>O revealed the presence of three distinct naphthol units (Table S12, Fig. S38–S50<sup>†</sup>), which were likely derived from **7**, **9** and **10** (Fig. 4B). The NMR spectra also clearly showed that one of the three naphthol units was methylated at 6-OH (corresponding to **10**), supporting the function of ElcD as an O-methyltransferase. Although the structure of **16** could not be unequivocally confirmed due to the presence of multiple contiguous non-protonated carbons, detailed analysis of the 1D and 2D NMR data in both D<sub>2</sub>O and DMSO- $d_6$  allowed us to propose a tentative structure in which the three naphthol units are linked *via* a central 5-membered ring (Fig. 4B). A similar cyclic trimeric construct was reported for the fungal antibiotic PF1158A, which is comprised of three semiovioxanthin monomers.<sup>24</sup> The experimental <sup>13</sup>C NMR shifts for **16** were also in close agreement with DFT-calculated shielding tensors for the proposed structure (Table S13<sup>†</sup>).

We next co-expressed *elcE* with *elcA/B/D* (pYFAC-CH10/11/16) to test its potential role in oxidative coupling as previously proposed. However, this resulted in no major change in metabolic profile compared to *A. nidulans* expressing *elcA/B/D* only (Fig. 4A-iv). The production of the perylenequinone-like **12** and **6** could only be reconstituted when later *elcF* and *elcG* were introduced together with *elcA/B/D/E* in *A. nidulans* (Fig. 4-v). In the absence of either *elcE* or *elcG*, there was no production of **12** and **6** (Fig. S10A<sup>†</sup>). On the other hand, the results from omitting *elcF* only varied between transformants and batches (Fig. S10B<sup>†</sup>). In some cases, we observed reduced production of **12** and **6**, while in others **12** and **6** production was completely abolished. Addition of *elcC* encoding major facilitator superfamily transporter also had no major effects on the yield of **12** and **6** (Fig. S10A<sup>†</sup>).

Finally, we included all the genes *elcA/B/D/E/F/G* in two instead of three YFACs and this resulted in increased yield of **12** and **6** and reduced production of shunt intermediates (Fig. 4-vii). This suggested that the accumulation of more shunt intermediates when the genes are split into three YFACs could be due to the poor stability of the intermediates and the episomal nature of the YFACs. As was observed for the episomal expression system in yeast,<sup>25</sup> some fungal cells may not contain all three YFACs.

### Cognate pairing of *ElcE*/*CTB5* and *ElcG*/*Cz\_CT B12* is required for perylenequinone formation

The accumulation of shunt products and the lack of an oxidative coupling intermediate with a single C–C bridge between two naphthol monomers observed in *A. nidulans* expression strains without either *elcE* or *elcG* suggested that *ElcE* and *ElcG* could work concurrently, perhaps in the form of a protein complex, to catalyse the two putative oxidative coupling steps. To investigate this possibility, we turned to the homologs of *elcE* and *elcG* from the biosynthetic pathway of **4**, *CTB5* and *CTB12*, respectively. As

no genome sequence for *C. nicotianae* was available when the experiment was carried out, we switched to another plant pathogen of the same genus, *Cercospora zeaе-maydis*, for which the genome sequence is available and has been reported to produce **4**.<sup>26</sup> A BLAST search using *ElcF* and *ElcG* against the *C. zeaе-maydis* genome identified homologs of both proteins (*Cerzm1/106448* and *Cerzm1/43209*, herein referred to as *Cz\_CT B11* and *Cz\_CT B12*), which are located ~15 kbp downstream of the corresponding *CTB* cluster (Fig. 2A). This is consistent with the most recent report of *CTB11* and *CTB12*.<sup>13</sup> We synthesised the two genes based on the *C. nicotianae* *CTB5* and *C. zeaе-maydis* *Cz\_CT B12* sequences and introduced them into the YFAC expression system. pYFAC-CH25 was constructed by replacing *elcE* in pYFAC-CH11 with *CTB5*, and pYFAC-CH26 was constructed by replacing *elcG* in pYFAC-CH12 with *Cz\_CT B12*. The constructs above were used in different combinations to test if the *elc* homologs could be complemented by the *CTB* counterpart. The results showed that when either *Cz\_CT B12* or *CTB5* was used to replace their *elc* counterpart individually, production of **12** and **6** was abolished. However, when they were both introduced together replacing *elcE* and *elcG*, two new peaks **19** and **20**, both with a perylenequinone-like UV-vis spectrum and  $m/z$  of 533  $[M + H]^+$ , were detected, along with trace amount of **12** and **6** (Fig. 5A). The **19** and **20** pair is reminiscent of the **12** and **6** stereoisomers. Due to low yield, the **19** and **20** structures were not fully characterised. However, <sup>1</sup>H-NMR spectra of both **19** and **20** and the HMBC correlations suggested that they have the same cyclohepta(*ghi*)perylenequinone framework as **12** and **6**, but lack the methyl group on 6-OH (Table S14, Fig. S51–S58<sup>†</sup>). HR-MS of **19** and **20**




Fig. 5 Homologous gene swapping (*elcE* with *CTB5*, *elcG* with *Cz\_CT B12* or both together) revealed the requirement for cognate pairing in perylenequinone production. (A) LC-DAD chromatograms of *A. nidulans* culture with YFAC constructs with different gene combination and (B) the structure and UV-vis spectra of **19/20**.



revealed ions with  $m/z$  533.1410  $[M + H]^+$ /531.1292  $[M - H]^-$  and 533.1414  $[M + H]^+$ /531.1290  $[M - H]^-$ , respectively. The predicted formula  $C_{29}H_{24}O_{10}$  (calculated  $m/z$  533.1414  $[M + H]^+$ /531.1290  $[M - H]^-$ ) (Fig. S9†) also corresponds to the loss of one methyl group. Collectively, the results showed that cognate pairing of ElcE/CTB5 and ElcG/Cz\_CTB12 is required for the double coupling, supporting the hypothesis for protein–protein interaction between the two different classes of oxidases.

## Discussion

The oxidative double coupling step, which forges the two C–C bridges between two highly functionalised naphthol units to complete the perylenequinone core that confers photochemical properties, has proven to be challenging to untangle. As in previous studies,<sup>7,13</sup> this current work involving gene deletion of candidate oxidase genes resulted in no tractable intermediate. Thus, we adopted both top-down (intact whole gene cluster) and bottom-up (gene-by-gene pathway reconstruction) heterologous reconstitution approaches to shed light onto perylenequinone biosynthesis. The modular nature of the tripartite YFAC *Aspergillus* expression system allowed the efficient construction of *A. nidulans* strains carrying YFACs with different gene combinations. In total, we constructed 22 *A. nidulans* strains, analysed the metabolite profiles and isolated three novel shunt intermediates plus two side hypocrellin products.

In light of all the results, we propose a revised biosynthetic pathway (Fig. 6). As in previous studies,<sup>11,12</sup> the first isolatable intermediate is the product of the PKS, nor-toralactone **7**, common to all Class B perylenequinone pathways. The subsequent steps, methylation of **7** followed by an oxidative ring cleavage and decarboxylation by ElcB (CTB3 homolog) to form **9**, are in agreement with the literature.<sup>7</sup> Previous *in vitro* enzymatic experiments suggested that **9** is highly reactive and spontaneously oxidised to naphthoquinones.<sup>7</sup> Likewise, we were unable to detect **9** when co-expressing *elcA* and intact *elcB*, however, the *A. nidulans* strain produced **13–15**. Compound **15** was hypothesised to be one of the cercoquinones, while **13** and **14** are both novel compounds containing an unusual fusion between a 1,2-naphthoquinone, a 2-methylpyrrole and thiazepane. The presence of an additional glycol moiety in **14** suggests that **13** and **14** are likely derived from a glutathione adduct of **9** formed *via* the common GST detoxification pathway in eukaryotes. An example of secondary metabolite thiolation mediated by GST is the gliotoxin pathway.<sup>27</sup> We propose that *O*-methylation of **9** to **10** by ElcD is the next step in perylenequinone biosynthesis after ElcB. Even though we did not directly detect **10** in the *A. nidulans* expressing *elcA/B/D*, the strain produced a new heterotrimeric compound **16** as an unusual adduct of **7**, **9**, and **10** (Fig. 6), likely catalysed by endogenous oxidases in the host. The presence of a 6-OME group on the naphthol unit corresponding to **10** on **16** demonstrates ElcD catalyse the 6-*O*-methylation as expected.

Stereo- and regio-selective oxidative coupling of polycyclic aromatic compounds have been shown to be catalysed by P450s in fungi.<sup>28–30</sup> More recently, a LMCO from the fungus *Talaromyces pinophilus* that could catalyse the regioselective coupling

of naphthopyranone was discovered.<sup>31</sup> The involvement of LMCOs in regioselective oxidative coupling of naphthopyrones have also been reported.<sup>32,33</sup> The oxidative coupling of the two monomeric naphthol units in perylenequinone biosynthesis was originally proposed to be catalysed by the ElcE homolog, *C. nicotianae* CTB5, which encodes a BBEO.<sup>7</sup> In the most recent study based on gene deletion results,<sup>13</sup> it was proposed that the LMCO CTB12 (ElcG homolog) catalyses the oxidative dimerisation instead. Here, we demonstrate conclusively by heterologous biosynthesis that both BBEO and LMCO are required for the double coupling step of the putative intermediate **10** to afford the pentacyclic perylenequinone system in **11**, which was converted to **12** and **6** in *A. nidulans*. By gene swapping with CTB homologs, we further demonstrated that cognate pairing of the BBEO and the LMCO is required for their catalytic function and that it could involve the formation of a protein complex. Interestingly, a new pair of hypocrellins **19** and **20** were observed in *A. nidulans* expressing CTB5/Cz\_CTB12 in place of ElcE/ElcG. From limited <sup>3</sup>H and 2D NMR data (due to poor yield), we deduced that **19** and **20** originated from coupling between **9** and **10**, while **12** and **6** are dimers of **10**. As there was no prior report of the equivalent of **19** and **20**, it is possible that this was an artefact of CTB5 and Cz\_CTB12 operating in ElcA/B/D/F background and suggests there may be other protein–protein interactions involved (*e.g.* ElcF), which requires further investigation (Fig. S11†).

Given that there are several precedents for LMCOs involved in intermolecular phenolic coupling,<sup>31–33</sup> we propose that the ElcG LMCO catalyses the first intermolecular coupling of **10** in a regio- and stereo-selective manner *via* a phenol radical coupling mechanism (Fig. 6-i). On the other hand, the ElcE BBEO could forge the second C–C bond intramolecularly *via* a hydride transfer mechanism similar to other BBEOs then further oxidation to **11** (Fig. 6-i). However, there are no reports of LMCOs that can catalyse stereo-selective oxidative coupling to date. In plants, the regio- and stereo-selective coupling reactions by LMCOs have been demonstrated to be facilitated by a dirigent protein.<sup>34,35</sup> It is unknown if protein–protein interactions between the ElcE and ElcG or the fasciclin protein ElcF could play a role in the regio- and stereo-selective coupling of perylenequinones. Although BBEOs are known to catalyse intramolecular C–C bond formation,<sup>21,36</sup> their involvement in such intramolecular phenolic coupling is unprecedented. Nonetheless, future *in vitro* investigation of the enzymes with compatible synthetic substrates is required to resolve these questions.

The last piece of the puzzle in the biosynthesis of **1** is the additional annulation by enolate coupling to afford the dihydrobenzo(*ghi*)perylenequinone system, which we showed to involve the FMO ElcH. Although enolate coupling is widely exploited in synthesis, there is little if any precedent in biosynthesis so far. Addition of *elcH* to *A. nidulans* expressing the *elc* cluster (*elcA/B/C/D/E/F/G*) resulted in the production of **1** and loss of production of **12** and **6**. We propose that **1** is formed through the putative perylenequinone intermediate **11** *via* a radical mechanism initiated *via* a single electron transfer from an enolate at the side chain to the FAD in ElcH (Fig. 6-ii). In the absence of ElcH, the hypocrellins **12** and **6** were formed,






Fig. 6 Revised biosynthetic pathway for dihydrobenzo(*ghi*)perylenequinone **1** and cyclohepta(*ghi*)perylenequinones **6** and **12**. (Box) Proposed mechanisms for the naphthol double coupling to forge the pentacyclic perylenequinone core (i), the enolate coupling to form the dihydrobenzo(*ghi*)perylenequinone in **1** (ii), and the two *syn* aldol reactions followed by atropisomerisation that afford **6** and **12**.

suggesting that **12** and **6** are most likely derived from the putative intermediate **11** via a transannular aldol reaction.

A dilemma emerged when we solved the configuration and helicity of **12** (*atrop*-5) and **6**, which is opposite to **1** and **3** that adopt an (*M*) conformation. We propose that in the formation of the two (*P*) hypocrellins **12** and **6**, (*M*)-**11** is first converted to (*M*)-**12** and (*M*)-**6** via the two possible transannular *syn* aldol reactions followed by spontaneous atropisomerisation to afford (*P*)-**12** and (*P*)-**6**, respectively (Fig. 6-iii). The facile atropisomerisation of **6** has been reported in several studies;<sup>1,37,38</sup> which demonstrated that the seven-membered ring in **6** reduced the stability of perylenequinone axial chiralities and allowed atropisomerisation at room temperature. By contrast, higher energy is required for atropisomerisation of pentacyclic perylenequinones, e.g. calphostin.<sup>3</sup> Indeed, our DFT calculations supported this (Fig. S12<sup>†</sup>). We found that the conversion of

(*M*)-**11** to (*M*)-**12** and (*M*)-**6** is associated with Gibbs free reaction barrier heights of 11.8 and 74.8 kJ mol<sup>-1</sup>, respectively (Fig. S12<sup>†</sup>), which indicate that both pathways are kinetically accessible at the temperature the experiments were carried out (30 °C). The (*P*)-**12** and (*P*)-**6** products lie 11.2 and 19.7 kJ mol<sup>-1</sup> below the energy of the (*M*)-**11** reactant, respectively, indicating a thermodynamic driving force for the conversion of (*M*)-**12** and (*M*)-**6** to atropisomerism to the (*P*) form. We have also observed that leaving **12** and **6** in methanol for prolonged periods resulted in partial conversion of the two (*P*) hypocrellins into what appear to be their corresponding (*M*) atropisomers (Fig. S13<sup>†</sup>). Thus, ElcH essentially locks the perylenequinone in the (*M*) helical conformation by converting **11** to **1**.

Nonetheless, we cannot rule out that the aldol reaction could involve endogenous *A. nidulans* enzymes, especially given that the energy barrier for (*M*)-**11** to (*M*)-**12** is higher than to (*M*)-**6**,



and that (*P*)-12 has never been reported previously. The transannular aldol reaction followed by atropisomerisation is reminiscent of the dynamic stereochemical transfer approach employed by Kozłowski *et al.* in the total synthesis of (*P*)-6, which is derived from (*P*)-11 in their synthetic route instead of (*M*)-11.<sup>37</sup> Interestingly, we did not isolate any shiraiachrome A or hypocrellin 5, which adopt the (*M*) helicity (Fig. 1); it is to be determined if the aldol reaction to these two compounds are enzymatically catalysed. A *Shiraia* sp. strain was previously reported to produce both 1 and 6, along with 2, 3 and hypocrellin B-C.<sup>39</sup> It is possible that the (*P*)-hypocrellins in this *Shiraia* strain were derived from an (*M*) perylenequinone precursor 11 like we have observed here.

In summary, using a heterologous pathway reconstruction approach we demonstrated the involvement of two different classes of oxidases (LMCO and BBEO) in the synthesis of the pentacyclic core common to all perylenequinones. The isolation of different shunt products 13, 14 and 16 that trapped the highly reactive naphthol intermediates provided insights into the biosynthetic step and suggests that *A. nidulans* is an excellent strain for biotransformation to generate novel naphthol derivatives. Finally, the identification of the elsinochrome synthase ElcH and the isolation of hypocrellin side products 6 and 12 allowed us to establish the biosynthetic link between the three subclasses of perylenequinones (Fig. 1).

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This study was supported by an Australian Research Council (ARC) Discovery Project (DP170100228). Y-HC, AK and AMP are ARC Future Fellows (FT160100233, FT170100373, FT130100142). NMR and HR-MS analyses were performed at the UWA Centre for Microscopy, Characterisation and Analysis (CMCA). JH and HL are both recipients of Australian International Postgraduate Research Scholarship. We thank Prof. Berl Oakley for *A. nidulans* strain LO7890 and Prof. Kenji Watanabe for the pKW20088 plasmid.

## References

- C. A. Mulrooney, B. J. Morgan, X. Li and M. C. Kozłowski, *J. Org. Chem.*, 2009, **75**, 16–29.
- M. Olivo and W. W. Chin, *J. Environ. Pathol., Toxicol. Oncol.*, 2006, **25**, 223–237.
- B. J. Morgan, S. Dey, S. W. Johnson and M. C. Kozłowski, *J. Am. Chem. Soc.*, 2009, **131**, 9413–9425.
- M. E. Daub, S. Herrero and K.-R. Chung, *Antioxid. Redox Signaling*, 2013, **19**, 970–989.
- S. Kuyama and T. Tamura, *J. Am. Chem. Soc.*, 1957, **79**, 5726–5729.
- H.-Q. Chen, M.-H. Lee and K.-R. Chung, *Microbiology*, 2007, **153**, 2781–2790.
- A. G. Newman and C. A. Townsend, *J. Am. Chem. Soc.*, 2016, **138**, 4219–4228.
- C. Yu, T. Huang, Z. Ding, X. Gao and Z. Zhang, *Encyclopedia of Chinese Medicines*, Chinese Medicinal Science and Technology Press, Beijing, People's Republic of China, 1993.
- H. Yang, Y. Wang, Z. Zhang, R. Yan and D. Zhu, *Genome Announc.*, 2014, **2**, e00011–00014.
- H. Deng, R. Gao, X. Liao and Y. Cai, *J. Biotechnol.*, 2017, **259**, 228–234.
- Y. H. Chooi, G. Zhang, J. Hu, M. J. Muria-Gonzalez, P. N. Tran, A. Pettitt, A. G. Maier, R. A. Barrow and P. S. Solomon, *Environ. Microbiol.*, 2017, **19**, 1975–1986.
- A. G. Newman, A. L. Vagstad, K. Belecki, J. R. Scheerer and C. A. Townsend, *Chem. Commun.*, 2012, **48**, 11772–11774.
- R. de Jonge, M. K. Ebert, C. R. Huitt-Roehl, P. Pal, J. C. Suttle, R. E. Spanner, J. D. Neubauer, W. M. Jurick, K. A. Stott, G. A. Secor, B. P. Thomma, Y. Van de Peer, C. A. Townsend and M. D. Bolton, *Proc. Natl. Acad. Sci. U. S. A.*, 2018, **115**, E5459–E5466.
- Y. Tsunematsu, N. Ishikawa, D. Wakana, Y. Goda, H. Noguchi, H. Moriya, K. Hotta and K. Watanabe, *Nat. Chem. Biol.*, 2013, **9**, 818.
- Y. M. Chiang, M. Ahuja, C. E. Oakley, R. Entwistle, A. Asokan, C. Zutz, C. C. Wang and B. R. Oakley, *Angew. Chem.*, 2016, **128**, 1694–1697.
- H. Wu, X.-F. Lao, Q.-W. Wang, R.-R. Lu, C. Shen, F. Zhang, M. Liu and L. Jia, *J. Nat. Prod.*, 1989, **52**, 948–951.
- Y.-H. Chooi and P. S. Solomon, *Front. Microbiol.*, 2014, **5**, 640.
- S. V. Ipcho, J. K. Hane, E. A. Antoni, D. Ahren, B. Henrissat, T. L. Friesen, P. S. Solomon and R. P. Oliver, *Mol. Plant Pathol.*, 2012, **13**, 531–545.
- J. E. DiCarlo, J. E. Norville, P. Mali, X. Rios, J. Aach and G. M. Church, *Nucleic Acids Res.*, 2013, **41**, 4336–4343.
- L. A. Kelley, S. Mezulis, C. M. Yates, M. N. Wass and M. J. Sternberg, *Nat. Protoc.*, 2015, **10**, 845.
- M.-C. Tang, Y. Zou, K. Watanabe, C. T. Walsh and Y. Tang, *Chem. Rev.*, 2016, **117**, 5226–5333.
- S. Fillinger and B. Felenbok, *Mol. Microbiol.*, 1996, **20**, 475–488.
- H. Li, J. Hu, H. Wei, P. S. Solomon, D. Vuong, E. Lacey, K. A. Stubbs, A. M. Piggott and Y.-H. Chooi, *Org. Lett.*, 2018, **20**, 6148–6152.
- M. Hatsu, N. Takei, F. Someya, T. Yaguchi, M. Nagasawa, S. Ishii and Y. Kurata, Japan Pat., JP 08208677, 1996.
- N. B. Jensen, T. Strucko, K. R. Kildegaard, F. David, J. Maury, U. H. Mortensen, J. Forster, J. Nielsen and I. Borodina, *FEMS Yeast Res.*, 2014, **14**, 238–248.
- W.-B. Shim and L. D. Dunkle, *Physiol. Mol. Plant Pathol.*, 2002, **61**, 237–248.
- D. H. Scharf, P. Chankhamjon, K. Scherlach, T. Heinekamp, K. Willing, A. A. Brakhage and C. Hertweck, *Angew. Chem., Int. Ed.*, 2013, **52**, 11092–11095.
- A. Präg, B. r. A. Grüning, M. Häckh, S. Lüdeke, M. Wilde, A. Luzhetsky, M. Richter, M. Luzhetska, S. Günther and M. Müller, *J. Am. Chem. Soc.*, 2014, **136**, 6195–6198.



- 29 C. Gil Girol, K. M. Fisch, T. Heinekamp, S. Günther, W. Hüttel, J. Piel, A. A. Brakhage and M. Müller, *Angew. Chem., Int. Ed.*, 2012, **51**, 9788–9791.
- 30 S. Griffiths, C. H. Mesarich, B. Saccomanno, A. Vaisberg, P. J. De Wit, R. Cox and J. Collemare, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, 6851–6856.
- 31 M. Kawaguchi, T. Ohshiro, M. Toyoda, S. Ohte, J. Inokoshi, I. Fujii and H. Tomoda, *Angew. Chem.*, 2018, **130**, 5209–5213.
- 32 W. Fang, S. Ji, N. Jiang, W. Wang, G. Y. Zhao, S. Zhang, H. M. Ge, Q. Xu, A. H. Zhang, Y. L. Zhang, Y. C. Song, J. Zhang and R. X. Tan, *Nat. Commun.*, 2012, **3**, 1039.
- 33 R. J. Frandsen, C. Schütt, B. W. Lund, D. Staerk, J. Nielsen, S. Olsson and H. Giese, *J. Biol. Chem.*, 2011, **286**, 10419–10428.
- 34 L. B. Davin, H.-B. Wang, A. L. Crowell, D. L. Bedgar, D. M. Martin, S. Sarkanen and N. G. Lewis, *Science*, 1997, **275**, 362–366.
- 35 T. Wezeman, S. Bräse and K.-S. Masters, *Nat. Prod. Rep.*, 2015, **32**, 6–28.
- 36 J. A. Baccile, J. E. Spraker, H. H. Le, E. Brandenburger, C. Gomez, J. W. Bok, J. Macheleidt, A. A. Brakhage, D. Hoffmeister and N. P. Keller, *Nat. Chem. Biol.*, 2016, **12**, 419–424.
- 37 E. M. O'Brien, B. J. Morgan, C. A. Mulrooney, P. J. Carroll and M. C. Kozlowski, *J. Org. Chem.*, 2009, **75**, 57–68.
- 38 A. Smirnov, D. B. Fulton, A. Andreotti and J. W. Petrich, *J. Am. Chem. Soc.*, 1999, **121**, 7979–7988.
- 39 Z. Tong, L. Mao, H. Liang, Z. Zhang, Y. Wang, R. Yan and D. Zhu, *J. Liq. Chromatogr. Relat. Technol.*, 2017, **40**, 536–540.

